I am excited to make cutting edge cancer care accessible to patients in the local community clinics.
Tina Wang, M.D. began thinking about a career in medicine and oncology while still in high school, when a family friend passed away from lymphoma. “As I started to study more about the biology of cancer, I became much more interested in how cancer grows and ways to stop the growth,” she says.
Dr. Wang specializes in breast, liver and lung cancer, with a particular focus on recent advances in immunotherapy. She is board certified in hematology, oncology, and internal medicine.
An honors student from Stanford University, Dr. Wang received her medical degree at the University of Texas, where she was a member of the Alpha Omega Alpha Honor Society. She completed her residency and fellowship at UCLA. She also did immunology research at MD Anderson Cancer Center in Houston, TX. Prior to joining City of Hope, she was an assistant professor at UCLA.
Dr. Wang puts a high priority on building relationships with her patients. She is also passionate about serving the larger community as a lecturer and educator in both English and Mandarin.
2016, American Board of Internal Medicine - Hematology
2016, American Board of Internal Medicine - Oncology
2013, American Board of Internal Medicine
2010, M.D., Alpha Omega Alpha Honor Society, University of Texas Health Science Center School of Medicine, San Antonio, Texas
2006, B.S., Biological Sciences, with Departmental Honors, Stanford University, Stanford, California
2013-2016, Fellow, Hematology/Oncology, University of California, Los Angeles, California
2010-2013, Resident, Internal Medicine, University of California, Los Angeles, California
2018-present - Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California
2016-2018 - Assistant Clinical Professor, Division of Hematology-Oncology, UCLA Medical Center, Los Angeles, California
Awards & Memberships
2013, American Society of Clinical Oncology
2013, American Society of Hematology
2011, American College of Physicians
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, M, Hunt J, Wolf B, Jones B, Madrigal J, Garon EB. “A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC,” Journal of Thoracic Oncology, in press.
Hsu M, Sedighim S, Wang T, Everson E, Tucker A, Antonios J, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Gang L, Liau L, Prins R. “TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patients,” Cancer Immunology Research, 2016, May.
Rawal S, Chu F, Kannan S, Zhang M, Percivalle E, Delgado D, Chou T, Sharma R, Davis R, Neelapu S. “Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment,” Journal of Immunology, 2013 June.
Chou T, Finn RS, Garon EB. “Expanding Options for EGFR Targeting in Lung Cancer,” Translational Lung Cancer Research, 2012 Dec.
Chou T, Finn RS. “Brivanib: a review of development,” Future Oncology, Sept 2012.
G. Trapp, K. Sydow, M. T. Dulay, T. Chou, J. P. Cooke, and R. N. Zare, "Capillary Electrophoretic and Micellar Electrokinetic Separations of Asymmetric Dimethyl-L-arginine and Structurally Related Amino Acids: Quantitation in Human Plasma," J. Sep. Sci. 2004 Dec.
Wang T. “Breast Cancer Survivorship.” Huntington Hospital and Herald Cancer Association 12th Annual Pink Ribbon Conference, Oct 2018. Lecture presentation.
Lisberg A, Hunt J, Reese N, Wang T, Goldman J, Garon E. “A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients with Advanced NSCLC.” IASLC 17th Annual Targeted Therapies of the Treatment of Lung Cancer, February 2017. Poster presentation.
Wang T. “Cancer Care in the Elderly.” Alhambra Hospital Medical Center 10th Annual Geriatric Symposium, November 2016. Lecture presentation.
Chou T, Pietras R, Goodglick L, Garon E. “Phase I dose escalation study of carboplatin, pemetrexed and exemestane in post-menopausal women with metastatic non-squamous NSCLC.” UCLA Solomon Scholars Research Day, June 2012. Poster presentation.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Show respect for what you say
Know important info medical history
Spend enough time with you
Recommend this provider office
Provider explain in way you understand
Provider listen carefully to you
Rate provider 0-10
Good - Verified patient
Good - Verified patient
I was nervous to get the iv treatment. Dr. Wang so kind and calm. Listened to all my concerns and addressed every on. I trust her completely. I know she cares. - Verified patient
One thing that I like about Dr. Wang is that she is very receptive to calling me back with information when I request it or test results etc. As a cancer patient it is very much appreciated. - Verified patient